measured before (0.66 6 0.32 cm) and after treatment (0.43 6 0.23 cm). As expected, erythema, swelling, and scale formation were observed in all the patients, with no further complications. 
Incidence of androgenic dermatologic side effects following placement of a levonorgestrel intrauterine device for menorrhagia: A survey-based study To the Editor: Dermatologic manifestations of hyperandrogenic states include acne vulgaris, alopecia, and hirsutism and result from the excess stimulation of the pilosebaceous unit. A synthetic progestin, levonorgestrel, is a methyl testosterone derivative. When orally administered, it has been associated with acne, with a reported incidence between 5% and 20%. 1 In contrast, given its localized effect, a levonorgestrel intrauterine device 52 mg (LNG-IUD) produces lower systemic levels of progestogens than with oral administration and, hence, is believed to have fewer systemic adverse effects. Existing literature has demonstrated the development of Description of the averages of fiber percentages found in the streak specimens in their respective staining, with the differences found through the Wilcoxon test. The measurements were performed in m 2 and the data expressed in proportional area of fibers in relation to the selected area in the slice (%). RF, Resorcine fucsine; SD, standard deviation; SG, striae gravidarum.
worsening acne in 6% of LNG-IUD users.
2,3 A more recent study found that 36% of hormone IUD users experienced worsened acne. 4 Given the wide use of LNG-IUD and the sparse data on this specific topic, this institutional review boardeapproved study sought to determine the incidence of skin-related hormonal side effects such as acne, hirsutism, and/or hair loss in women who had a LNG-IUD placed for the treatment of menorrhagia.
A survey regarding hyperandrogenic states, including polycystic ovary syndrome, acne, alopecia, and hirsutism, was sent electronically and via postal mail to 206 patients who had an LNG-IUD 52 mg (which is approved for 5-year use) inserted between 2010 and 2015. The incidence of hyperandrogenic states in this group was analyzed.
A total of 51 patients (25%) responded to the survey. There was a significant (P ¼ .0005) change in acne severity upon LNG-IUD placement. Of the 51 responders, 35% had worsened acne, 4% had improved acne, and 61% had no change in acne. LNG-IUD use was not significantly associated with alopecia (P ¼ .18). However, 20% of women reported worsened hair loss after LNG-IUD placement, whereas 76% and 4% had no change and improved hair loss, respectively. Although 41% of participants noted excess facial hair upon its placement, no significant association (P ¼ .43) was noted between LNG-IUD use and hirsutism.
Our data demonstrate a higher rate of acne worsening after LNG-IUD insertion than in initial studies. This survey corroborates the more recent findings regarding the association of worsening acne with use of the LNG-IUD.
Study limitations included a nonresponse and possible recall bias among survey participants, as well as a small total sample size. These may be attributed to the higher than typically reported incidence of acne among participants in our study. However, these findings add to the growing body of literature that supports a strong association of acne exacerbation with use of the LNG-IUD. This undesirable adverse effect should be discussed with patients who are considering the LNG-IUD as a therapeutic option. For those patients desiring to retain their LNG-IUD despite acne exacerbation, topical retinoids, topical and oral antibiotics, and the androgen receptor modulator spironolactone have been used with clinical therapeutic benefit, although removal of the LNG-IUD may be indicated in severe or refractory cases. 5 In our experience, IUD-associated acne can be controlled with low-dose spironolactone (25-100 mg daily). However, dedicated clinical studies examining optimal management of LNG-IUDeassociated acne are warranted.
https://doi.org/10.1016/j.jaad.2017.12.051
Efficacy of NB-UVB, microneedling with triamcinolone acetonide, and a combination of both modalities in the treatment of vitiligo: A comparative study To the Editor: Vitiligo has a great impact on the physical and mental health of patients, including loss of skin photoprotection, impaired cutaneous immunity, and marked reduction in quality of life. Therapeutic options for stabilizing and repigmenting vitiligo have been modestly expanded in recent years without a completely satisfactory outcome. 1 Narrowband ultraviolet B (NB-UVB) is considered the criterion standard in vitiligo treatment, with a high repigmentation rate that is further
